The Mycobacterium tuberculosis Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Mycobacterium tuberculosis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mycobacterium tuberculosis Infections. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mycobacterium tuberculosis Infections and features dormant and discontinued products.

GlobalData tracks 256 drugs in development for Mycobacterium tuberculosis Infections by 182 companies/universities/institutes. The top development phase for Mycobacterium tuberculosis Infections is preclinical with 117 drugs in that stage. The Mycobacterium tuberculosis Infections pipeline has 156 drugs in development by companies and 100 by universities/ institutes. Some of the companies in the Mycobacterium tuberculosis Infections pipeline products market are: GSK, Global Alliance for TB Drug Development and Quratis.

The key targets in the Mycobacterium tuberculosis Infections pipeline products market include Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI (NADH Dependent Enoyl ACP Reductase or Enoyl ACP Reductase or EC 1.3.1.9), FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase (Decaprenylphospho-Beta-D-Ribofuranose 2-Dehydrogenase or Decaprenylphosphoryl-Beta-D-Ribofuranose 2′-Epimerase 1 or dprE1 or EC 1.1.98.3), and H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2).

The key mechanisms of action in the Mycobacterium tuberculosis Infections pipeline product include Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI (NADH Dependent Enoyl ACP Reductase or Enoyl ACP Reductase or EC 1.3.1.9) Inhibitor with seven drugs in Phase II. The Mycobacterium tuberculosis Infections pipeline products include 11 routes of administration with the top ROA being Oral and 17 key molecule types in the Mycobacterium tuberculosis Infections pipeline products market including Small Molecule, and Subunit Vaccine.

Mycobacterium tuberculosis Infections overview

The group of infections caused by Mycobacterium tuberculosis (M. tuberculosis) are referred to as Mycobacterium tuberculosis infections, which primarily affect the lungs but can also impact other parts of the body. The symptoms include persistent cough, fever, weight loss, and night sweats. Treatment typically involves a combination of antibiotics taken over several months. M. tuberculosis infections remain a significant global health concern, with efforts focused on prevention, early diagnosis, and treatment to control its spread.

For a complete picture of Mycobacterium tuberculosis Infections’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.